Relmada Therapeutics Inc (NASDAQ: RLMD) has experienced a rise in its stock price by 15.47 compared to its previous closing price of 0.36. However, the company has seen a gain of 14.90% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Is It Worth Investing in Relmada Therapeutics Inc (NASDAQ: RLMD) Right Now?
Moreover, the 36-month beta value for RLMD is 0.14. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for RLMD is 27.81M and currently, short sellers hold a 7.32% of that float. On May 12, 2025, RLMD’s average trading volume was 1.75M shares.
RLMD’s Market Performance
RLMD stock saw an increase of 14.90% in the past week, with a monthly gain of 62.09% and a quarterly increase of 35.72%. The volatility ratio for the week is 12.37%, and the volatility levels for the last 30 days are 26.29% for Relmada Therapeutics Inc (RLMD). The simple moving average for the past 20 days is 7.50% for RLMD’s stock, with a -74.84% simple moving average for the past 200 days.
Analysts’ Opinion of RLMD
Many brokerage firms have already submitted their reports for RLMD stocks, with Mizuho repeating the rating for RLMD by listing it as a “Neutral.” The predicted price for RLMD in the upcoming period, according to Mizuho is $1 based on the research report published on December 05, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RLMD reach a price target of $13, previously predicting the price at $3.50. The rating they have provided for RLMD stocks is “Buy” according to the report published on September 17th, 2024.
Goldman gave a rating of “Sell” to RLMD, setting the target price at $2 in the report published on June 05th of the previous year.
RLMD Trading at 29.14% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.62% of loss for the given period.
Volatility was left at 26.29%, however, over the last 30 days, the volatility rate increased by 12.37%, as shares surge +46.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.05% upper at present.
During the last 5 trading sessions, RLMD rose by +14.90%, which changed the moving average for the period of 200-days by -89.49% in comparison to the 20-day moving average, which settled at $0.3902. In addition, Relmada Therapeutics Inc saw -19.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from TRAVERSA SERGIO, who purchase 51,407 shares at the price of $2.99 back on Sep 11 ’24. After this action, TRAVERSA SERGIO now owns 384,024 shares of Relmada Therapeutics Inc, valued at $153,707 using the latest closing price.
TRAVERSA SERGIO, the Chief Executive Officer of Relmada Therapeutics Inc, purchase 55,579 shares at $2.71 during a trade that took place back on Sep 09 ’24, which means that TRAVERSA SERGIO is holding 299,603 shares at $150,619 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -2.36. Equity return is now at value -132.33, with -111.57 for asset returns.
Currently, EBITDA for the company is -79.98 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
To wrap up, the performance of Relmada Therapeutics Inc (RLMD) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
